8-K: Accelerate Diagnostics Announces Preliminary Q4 and Full-Year 2024 Results, Anticipates FDA Submission for WAVE System

Accelerate Diagnostics reports preliminary 2024 results, highlighting progress with its WAVE system clinical trial and a reduction in cash burn.

Summary

• Accelerate Diagnostics announced preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024.
• The company is making progress on the clinical trial for its Accelerate WAVE system and Gram-Negative assay.
• They anticipate FDA submission for the WAVE system in the first quarter of 2025, with a potential commercial launch in late 2025.
• Preliminary revenue for 2024 was approximately $11.7 million, compared to $12.1 million in the prior year.
• Consumable product revenue increased by approximately 3%, but overall revenue decreased due to lower capital sales of Pheno instruments.
• The company ended the year with approximately $16.3 million in cash and cash equivalents, a decrease of $4.5 million in Q4 2024.
• This cash decrease reflects a continued reduction in operating cash use over the prior quarters of 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue is down, there's progress on the WAVE system and a reduction in cash burn. The forward-looking statements are cautiously optimistic.

Positives

• The company is making significant progress with its WAVE system clinical trial.
• They anticipate FDA submission for the WAVE system in Q1 2025.
• Consumable product revenue increased by approximately 3% year-over-year.
• The company is reducing its cash burn.
• Contract extensions with strategic customers are secured through the anticipated WAVE commercial launch.
• The Accelerate Arc system and BC kit received 510(k) clearance.

Negatives

• Preliminary revenue for 2024 was $11.7 million, down from $12.1 million in the prior year.
• The decrease in revenue was due to lower capital sales of Pheno instruments.
• Cash and cash equivalents decreased by $4.5 million in Q4 2024.

Risks

• The preliminary financial results are unaudited and subject to revisions.
• Actual results may differ materially from these preliminary results.
• The company's ability to obtain regulatory approvals is uncertain.
• Volatility throughout the global economy and the related impacts to the businesses of the company's suppliers and customers.
• Difficulties in resolving the company's continuing financial condition and ability to obtain additional capital to meet its financial obligations.
• Less than expected operating and financial benefits resulting from cost cutting measures.

Future Outlook

The company anticipates FDA submission for the WAVE system in the first quarter of 2025 and a commercial launch in late 2025. They also expect to announce full-year 2024 financial results in advance of its earnings conference call in March 2025.

Management Comments

• Jack Phillips, President and CEO, commented on the company's momentum across its innovation pipeline, progress in its commercial strategy, and meaningful reductions in cash burn.
• Mr. Phillips stated that the company believes it is close to finalizing enrollment for the clinical trial, with very encouraging results to-date.

Industry Context

Accelerate Diagnostics operates in the in vitro diagnostics market, focusing on rapid diagnosis of serious infections and antibiotic resistance. The development and potential commercialization of the WAVE system could position them competitively against other companies in the rapid antimicrobial susceptibility testing space.

Comparison to Industry Standards

• The document mentions that the Accelerate Pheno system offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
• This is a significant advantage compared to traditional methods, which can take several days.
• Companies like bioMérieux and Cepheid also offer rapid diagnostic solutions, but the specific time-to-result and features of Accelerate's WAVE system will determine its competitive positioning.

Stakeholder Impact

• Shareholders: The preliminary results and future outlook will impact shareholder value.
• Employees: The progress of the WAVE system and financial performance will affect employee morale and job security.
• Customers: The potential commercial launch of the WAVE system could provide improved diagnostic solutions.
• Suppliers: The company's financial performance and product development will impact supplier relationships.
• Patients: Faster diagnostic results could lead to better patient outcomes.

Next Steps

• Finalize enrollment for the WAVE system clinical trial.
• Submit the WAVE system for FDA approval in Q1 2025.
• Prepare for the commercial launch of the WAVE system in late 2025.
• Announce full-year 2024 financial results in March 2025.

Key Dates